MRK

NYSE

Merck & Co., Inc.

Health Care, Pharmaceuticals

$128.58

close 7 Aug 2026

+60.66%

52-week change

$317.57B

market cap

$77.58

$135.05

52-week range

Valuation

Market cap$317.57B

P/E (TTM / 5y avg)36.22x76.09x

Forward P/E (FY2026 / FY2027)46.87x13.39x

PEG (TTM / fwd)4.290.19

P/S (TTM)4.83x

P/B6.91x

EV/EBITDA (TTM)22.20x

FCF yield (TTM)4.44%

Cash flow & dividend

FCF (TTM)$14.12B

FCF per share (TTM)$5.71

FCF margin (TTM)21.46%

Dividend yield (indicated / 5y avg)2.64%3.06%

Annualized dividend$3.40

Payout ratio (EPS / FCF)92.12%51.66%

Growth & quality

Revenue YoY, latest Q+5.07%

Diluted EPS YoY, latest Q-130.68%

Operating margin (TTM)—

Net margin (TTM)13.59%

ROE (latest FY)34.70%

Net debt / EBITDA (TTM)4.32

Interest coverage (TTM)—

Price

+67.60%+10.92%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +9.38%10Y CAGR +5.11%

Diluted EPS

5Y CAGR +22.37%10Y CAGR +17.20%

FCF per share

5Y CAGR +32.73%10Y CAGR +2.71%

Operating cash flow

5Y CAGR +16.68%10Y CAGR +2.77%

Free cash flow

5Y CAGR +31.13%10Y CAGR +0.94%

Dividends per share

5Y CAGR +6.93%10Y CAGR +6.64%

Payout ratio

FCF payout ratio

FCF margin

Return on equity

Shares outstanding

5Y CAGR -1.20%10Y CAGR -1.73%

Net debt / EBITDA

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date29 Oct 2026

EPS estimate$2.30

Revenue estimate$17.52B

Last reported

Date—

EPS——

Revenue——